

Meningococcal Immunization Recommendations* Physician Resource

Meningococcal Vaccines Available in Canada

Vaccine	Publicly Funded Schedule (Ontario)		Manufacturer's Age Licensure in Canada
	Routine	High Risk	
Serogroup C only			
Menjugate® Meningitec® NeisVac-C®	12 months (Menjugate®)		≥ 2 months
Serogroup B only			
Bexsero®		2 months-17 years	2 months-17 years
Quadrivalent ACYW-135 (conjugate)			
Menactra® Menveo® Nimenrix®	Grade 7 (Menactra®)	≥ 9 months (Menactra®)	Menactra®: 9 months-55 years Menveo®: 2 months-55 years Nimenrix®: 12 months-55 years

Meningococcal C and ACYW-135 (conjugate) Immunization Healthy Patient

First Dose (Age)	Men C		Men ACYW-135 [§]	
	Recommendation	Publicly Funded (Y/N)	Recommendation	Publicly Funded (Y/N)
2-11 months	Individuals at increased risk of exposure. † (A booster dose given ≥ 12 months of age).	N	Individuals at increased risk of exposure† (e.g. travel, laboratory personnel, military).	N
12 months-11 years	Routine: 12 months of age (Menjugate®)	Y Born on or after 2003/09/01	Individuals at increased risk of exposure (e.g. travel, laboratory personnel, military).	N
12-18 years	Individuals at increased risk of exposure or if not previously received.	Y Born on or after 2003/09/01	Routine: Grade 7 (Menactra®) Offered through Health Unit only.	Y Born on or after 1997/01/01
≥ 19 years	Not recommended.	Y Born between 1986/01/01 and 1996/12/31 if not previously received.	Individuals at increased risk of exposure (e.g. travel, laboratory personnel, military).	N

Immunization of School Pupils Act (ISPA) requirements to attend school:

Men-C-C: 1 dose is required to be administered **on or after the 1st birthday**, regardless of any doses given in the first year of life.

Men-C-ACYW -135: 1 dose is required for students ≥12 years of age.

If 5 years have lapsed since a previous dose of Men-C-ACYW-135, it is **recommended** that students receive a publicly funded dose in Grade 7.

At least 4 weeks is required between doses of Men-C-ACYW-135 and Men-C-C.

For travel information:

Health risk based on destination: <http://www.phac-aspc.gc.ca/tmp-pmv/index-eng.php>.

Statement on Meningococcal Disease and the International Traveler-2015 (CATMAT):

<http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-05/com-2-eng.php>

Men-C-ACYW Boosters for travel: If age at first dose ≤ 7 years – boost every 3 to 5 years.

If age at first dose ≥ 7 years – boost every 5 years.

* Reference: National Advisory Committee on Immunization (NACI)

† Refer to Product Monograph for dosing schedule

§ Use appropriate product based on age

Meningococcal Immunization Recommendations* Physician Resource

Meningococcal B [4CMenB] Immunization (Bexsero®) Healthy Patient

NACI does not recommend 4CMenB vaccine for use in routine immunization programs. However, 4CMenB vaccine can be considered on an individual basis depending on the preference of the vaccine recipient and the risk of exposure for individuals ≥ 2 months of age.

Meningococcal B [4CMenB] Immunization (Bexsero®) High Risk Patient

Patient is high risk if they have the following medical conditions*:

- **Functional or anatomic asplenia**
- **Complement, properdin, factor D or primary antibody deficiencies**
- **Cochlear implant recipients (pre/post implants)**
- **Acquired complement deficiency (e.g. receiving eculizumab)**
- **HIV**

*The vaccine is publicly funded for children aged 2 months to 17 years with these conditions.

High Risk Meningococcal Immunization Program Vaccine Order Form: <http://peelregion.ca/health/professionals/tools/forms.htm>

Immunization Schedule For Healthy and High Risk Patients (Bexsero®)

First Dose (Age)	Publicly Funded (Y/N)	Immunization Schedule/Minimum Interval	Booster Schedule
2-5 months	Y (High Risk Children Only)	1st dose 2nd dose, 4 weeks after 1st dose 3rd dose, 4 weeks after 2nd dose 4th dose, 8 weeks after 3rd dose and at age ≥ 12 months	None
6-11 months		1st dose 2nd dose, 8 weeks after 1st dose 3rd dose, 8 weeks after 2nd dose and at age ≥ 12 months	
12 months to 10 years		1st dose 2nd dose, 8 weeks after 1st dose	
11 to 17 years		1st dose 2nd dose, 4 weeks after 1st dose	
≥ 18 years (off-label)	N	1st dose 2nd dose, 4 weeks after 1st dose	

Note: There are no spacing requirements between Meningococcal B vaccine and other Meningococcal vaccines.

For travel information:

Health risk based on destination: <http://www.phac-aspc.gc.ca/tmp-pmv/index-eng.php>

Statement on Meningococcal Disease and the International Traveler-2015 (CATMAT):

<http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-05/com-2-eng.php>

* Reference: National Advisory Committee on Immunization (NACI)

Meningococcal Immunization Recommendations* Physician Resource

Meningococcal ACYW-135 Immunization High Risk Patient

Patient is high risk if they have the following conditions:

- **Functional or anatomic asplenia**
- **Complement, properdin, factor D or primary antibody deficiencies**
- **Cochlear implant recipients (pre/post implants)**
- **Acquired complement deficiency (e.g. receiving eculizumab)**
- **HIV**

High Risk Meningococcal Immunization Program Vaccine Order Form: <http://peelregion.ca/health/professionals/tools/forms.htm>

First Dose (Age)	Vaccine(s)	Publicly Funded (Y/N)	Immunization Schedule	Booster Schedule
2 to 6 months	Menveo®	N	1st dose 2nd dose, 8 weeks after 1st dose 3rd dose, 8 weeks after 2nd dose 4th dose, 8 weeks after 3rd dose and at age ≥ 12 months [◇]	Boosters every 3 to 5 years
7 to 11 months	Menveo®	N	1st dose 2nd dose, 8 weeks after 1st dose and at age ≥ 12 months [◇]	Boosters every 3 to 5 years
9 to 11 months	Menactra®	Y	3 doses (8 week interval)	Boosters every 3 to 5 years
12 months to 6 years	Menactra®	Y	2 doses (8 week interval)	Boosters every 3 to 5 years
	Menveo® (Preferred product up until 2 years of age)	N		
	Nimenrix®	N		
7 to 55 years	Menactra®	Y	2 doses (8 week interval)	Boosters every 5 years
	Menveo®	N		
	Nimenrix®	N		
≥ 56 years Use ≥ 56 years of age is off-label for all Men-C-ACYW-135 products but considered appropriate based on expert opinion (Canadian Immunization Guide)	Menactra®	Y (One lifetime dose only)	2 doses (8 week interval)	Boosters every 5 years
	Menveo®	N		
	Nimenrix®			

Notes:

- Doses may be given at a minimum of 4 weeks apart if an accelerated schedule is required. When a series is initiated in infancy, one dose is to be administered at ≥ 12 months of age.
- At least 4 weeks is required between doses of Men-C-ACYW-135 and Men-C-C.
- Product supplied for high risk program may be substituted based on product availability.
- Menomune® (Men-P-ACYW-135) production has been discontinued.

[◇]As per Menveo® product monograph (2017).

* Reference: National Advisory Committee on Immunization (NACI)